Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells.
Diana SaleiroEwa M KosciuczukMariafausta FischiettiRicardo E PerezG Sohae YangFrank D EckerdtElspeth M BeauchampYe HouQixuan WangRona Singer WeinbergEleanor N FishFeng YueRonald HoffmanLeonidas C PlataniasPublished in: Cancer research communications (2023)
Our findings raise the potential for clinical development of drugs targeting CHAF1B to enhance IFN antitumor responses in the treatment of patients with MPN and should have important clinical translational implications for the treatment of MPN and possibly in other malignancies.